PEABODY, MASS. (August 19, 2005) – Analogic Corporation (NASDAQ: ALOG) announced the release and first customer orders for the LIFEGARDTM II family of non-invasive patient monitors.
The LIFEGARD II is the latest in a series of non-invasive patient monitors from Analogic. LIFEGARD II is the platform upon which the Company will expand its patient monitoring offerings. The first release consists of five models. The basic units measure five parameters, while other models also monitor continuous non-invasive cardiac output and end-tidal CO2. Units come equipped with integrated printers for documenting waveforms and parameter values. Additional models with expanded capabilities that have already received the U.S. Food & Drug Administration (FDA) clearance are to be made available over the next 12 months.
Lonnie Weaver, General Manager of Analogic’s Life Care Systems Division, noted, “The LIFEGARD II represents a significant expansion of our growing LIFEGARD family of non-invasive patient monitors. The non-invasive, portable LIFEGARD II family adds a new level of versatility to patient monitoring by allowing clinicians to more comprehensively monitor patient hemodynamics anywhere in the hospital or in non-acute environments such as a freestanding clinic or physician’s office. Clinicians can evaluate a patient in considerably less time and with no risk of infection, compared to conventional invasive monitoring modalities.”
For more information, visit Hall 14, Booth #B24-5 at MEDICA, www.analogic.com/lifegard or call 1-800-599-7769.